Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (349 records) with 2024 (223) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,836 records in scope (CR5), not by the ranked leaders only.
Imaging-based in situ profiling sits at the intersection of molecular detection and microscopy: methods for reading nucleic acid or protein signals directly inside intact tissue or cells, rather than after extraction. This landscape tracks patent filings that combine core techniques — in situ hybridization, in situ sequencing and multiplexed imaging — with the practical constraints that determine whether a method actually works at scale: optical crowding, decoding error rate, probe design, autofluorescence background, imaging cycle time and panel size limit.
The dataset spans 8,836 published records from January 2015 through July 2026, drawing on assignees ranging from diagnostics companies to academic medical centres. The claims here span everything from foundational probe chemistry to downstream bioinformatics pipelines, which is why the IPC composition below shows heavy overlap between molecular biology and analytical measurement classes.
Two views of the same 8,836 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
Annual filings rose from 322 in 2017 to a peak of 404 in 2022. Using only complete years, filings fell -36% from 349 in 2021 to 223 in 2024. Data for 2025 and 2026 is still incomplete because publication typically lags filing by roughly 18 months, so the apparent drop in the most recent one or two years should not be read as the field slowing further.
C12Q (measuring and testing involving enzymes or DNA) appears in 67.9% of the 8,836 records, far ahead of G01N (material analysis and testing) at 29.0% and C12N (microorganisms and genetic engineering) at 27.4%. Because a single record can carry multiple IPC classes, these shares add up to well over 100% — they show where claim density sits, not a partition of the field.
Shares are the percentage of the 8,836 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about imaging based in situ profiling and every answer comes back with the patent numbers behind it.
Try EurekaFiled by the University of Massachusetts, this 1998 filing discloses a method for removing autofluorescence background from microscopic or flow cytometry images by comparing fluorescence readings before and after "uncaging" a caged fluorochrome label on a probe. The approach applies to fluorescent in situ hybridization images and to tracking a target molecule inside a living cell, and it also discloses a fluorochrome-uncaging flow cytometer.One of the earliest filings in this dataset to directly address autofluorescence background as a named technical constraint, rather than treating it as incidental imaging noise.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5925517A | Detectably labeled dual conformation oligonucleotide probes, assays and kits | 2,942 |
| 2 | WO1997031256A2 | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays | 870 |
| 3 | US6103476A | Detectably labeled, dual conformation oligonucleotide probes, assays and kits | 673 |
| 4 | US6852487B1 | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays | 667 |
| 5 | WO2006084132A2 | Reagents, methods, and libraries for bead-based squencing | 585 |
| 6 | WO2008021290A2 | Organ-specific proteins and methods of their use | 521 |
| 7 | US7709198B2 | Multiplex detection of nucleic acids | 510 |
| 8 | US20130116130A1 | Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Label-Tags | 451 |
| 9 | US8951726B2 | Multiplex detection of nucleic acids | 432 |
| 10 | US8604182B2 | Multiplex detection of nucleic acids | 432 |
Ranked by citation count within the searched corpus. Older filings accumulate more citations simply by being available longer, so treat this as a measure of influence on subsequent filers, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three patterns stand out once volume, composition and citation data are read together.
The top 5 assignees combined account for 23.4% of the 8,836 records in scope, and the top 10 for 34.6%. That leaves roughly two-thirds of the field distributed across a long tail of the ranked leaders and unranked filers, which is unusual concentration for a field this size but still far from a lockout.
Filings peaked at 404 in 2022 after climbing from 322 in 2017. Using only complete years, the drop from 349 filings in 2021 to 223 in 2024 works out to -36% over that span — a real cooling, not an artifact of publication lag, since 2024 is the last year with a complete count.
C12Q leads at 67.9% of records, but G01N (29.0%), C12N (27.4%) and A61K (18.4%) all appear at meaningful share, and G16B bioinformatics classes still reach 9.6%. Most filings in this space combine a molecular or chemistry claim with an analytical or software claim rather than sitting in one class alone.
The most-cited record in this corpus, US5925517A on dual-conformation oligonucleotide probes, carries 2,942 citations, well ahead of the next-ranked filings. That concentration of citations on older foundational probe chemistry is typical of a searched corpus and signals influence on later filers rather than continued commercial relevance.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to imaging based in situ profiling, with the prior art for and against each one.
The ranked leaders span diagnostics firms, genomics platform companies and academic research institutions, with filing activity split between core probe chemistry and downstream analysis pipelines.
The top-ranked assignee holds 668 records, nearly three times the fifth-place total of 229. That gap suggests a sustained, multi-year filing programme rather than a single burst of activity.
One of the more prolific recent filers recorded only 3 filings in the latest tracked year, down 94% year-on-year, while several other ranked leaders show zero filings in that same window. This is consistent with the broader post-2022 cooling rather than an isolated event.
The strongest co-assignee pairing in this dataset accounts for 355 joint records, far ahead of the next pairing at 183. Only 10 co-assignee pairs are recorded overall, so most filers in this field are not filing jointly.
| Assignee | Recent year | YoY |
|---|---|---|
| 10x Genomics, Inc. | 3 | -94% |
| SomaLogic Operating Co., Inc. | 1 | -86% |
| Genomic Health, Inc. | 0 | — |
| aTyr Pharma, Inc. | 0 | — |
| Pangu Biopharma Limited | 0 | — |
| Kura Oncology, Inc. | 0 | — |
| Caris MPI, Inc. | 0 | -100% |
| Pioneer Hi-Bred International, Inc. | 0 | -100% |
The dataset points to a field with a crowded core and open edges. The next steps depend on whether the goal is freedom-to-operate, licensing, or identifying where to file next.
With 23.4% of records held by five assignees, a targeted clearance search against just the top-ranked holders will surface most of the blocking claims before a broader search is needed.
Run a freedom-to-operate check in EurekaPanel size scaling, decoding error correction and imaging cycle time show thinner filing density than core probe chemistry, making them candidates for new claim territory.
Explore white space in EurekaSeveral top assignees show zero or sharply declining recent filings, which can signal a shift in strategy, licensing-out, or a move to trade secret protection worth monitoring.
Set up assignee monitoring in EurekaOne assignee leads the ranked field with 668 records, well ahead of the fifth-placed assignee at 229 and the tenth at 178. The top 5 assignees combined hold 23.4% of all 8,836 records in scope, and the top 10 hold 34.6%. That leaves a substantial majority of filings spread across a long tail of smaller and single-filing entrants, so leadership at the top does not translate into control of the whole field.
Filing activity grew from 322 records in 2017 to a peak of 404 in 2022, then declined using complete-year data to 223 in 2024 — a -36% drop from the 349 filed in 2021. Figures for 2025 and 2026 are still incomplete because patent publication typically lags the actual filing date by around 18 months, so the most recent one to two years will rise as more records are published. Based on the complete-year trend through 2024, the field has genuinely cooled from its 2022 high.
The search underlying this landscape combines core methods — in situ hybridization, in situ sequencing and multiplexed imaging — with specific practical constraints: optical crowding, decoding error rate, probe design, autofluorescence background, imaging cycle time and panel size limit. In practice this means claims range from probe chemistry and signal amplification through to image processing and decoding algorithms that let a method scale beyond a handful of targets per tissue section.
C12Q, covering measuring and testing involving enzymes or DNA, appears in 67.9% of the 8,836 records in scope, making it by far the most common classification. G01N (material analysis and testing) follows at 29.0% and C12N (microorganisms and genetic engineering) at 27.4%, with A61K, C07K, G16B, C07H and A61P all present at meaningful shares. Because records often carry more than one IPC class, these percentages add up to well over 100%, reflecting how often molecular biology claims are paired with analytical or bioinformatics claims in the same filing.
The concentration data shows most of the field's volume sitting with a small number of assignees, but several technical sub-areas tied to the search terms — panel size scaling, decoding error correction, imaging cycle time reduction, and automated probe design — show comparatively thinner filing density than core probe chemistry. Momentum data also shows several previously active assignees with zero filings in the latest tracked year, which can indicate either a strategic pivot or an opening for new entrants. A targeted search against the specific claim language of the leading assignees is the right first step before filing in any of these branches.
Go past this page: query the whole imaging based in situ profiling corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page